Determinación del gen Ras como factor pronóstico y predictivo en cáncer colorrectal metastásico en el Instituto de Oncología Dr. Heriberto Pieter, enero 2019 - diciembre 2021
Date
Subject
Cáncer colorrectal
gen RAS
KRAS
valor pronostico
valor predictivo
caracterización molecular
análisis de supervivencia
evaluación de biomarcadores
colorectal cancer
RAS gene
KRAS
prognostic value
predictive value
molecular characterization
survival analysis
biomarker evaluation
gen RAS
KRAS
valor pronostico
valor predictivo
caracterización molecular
análisis de supervivencia
evaluación de biomarcadores
colorectal cancer
RAS gene
KRAS
prognostic value
predictive value
molecular characterization
survival analysis
biomarker evaluation
Language:
Journal Title
Journal ISSN
Volume Title
Publisher
Intituto Tecnológico de Santo Domingo (INTEC)
Objetivo:
Determinar el gen RAS como factor pronóstico y predictivo en cáncer colorrectal metastásico.
Método:
Es un estudio descriptivo y retrospectivo donde se examinaron 67 expedientes de pacientes con cáncer colorrectal metastásico, centrándose en la determinación del gen RAS como factor pronóstico y predictivo.
Resultados:
Se halló que el 56.7% de los pacientes tenían tumores Wild-type y el 43.3% mostraba tumores con mutaciones KRAS, sin detectarse mutaciones en el gen NRAS. Tanto en el colon derecho como en el izquierdo, los tumores Wild-type fueron algo más comunes que los tumores con mutaciones KRAS. El codón 12 fue el más afectado en un 75.9% de los casos de tumores KRAS mutados. El adenocarcinoma fue el tipo histológico predominante (82%), seguido del adenocarcinoma mucinoso (16.5%). La mayoría de los pacientes (56.7%) se hallaban en estadio IV al diagnóstico. Los tumores KRAS mutados mostraron una mayor tendencia a la recurrencia y metástasis múltiples en comparación con los tumores Wild-type, siendo el hígado y el pulmón los sitios más comunes de metástasis. También se observaron diferencias en la supervivencia libre de progresión y la supervivencia global según el estado mutacional del gen RAS, con una mayor progresión en pacientes con tumores KRAS mutados.
Conclusión:
Estos hallazgos sugieren que las mutaciones en el gen KRAS podrían asociarse con peor pronóstico en términos de progresión de la enfermedad y supervivencia. La determinación del estado del gen KRAS podría tener implicaciones clínicas significativas en la estratificación del riesgo y la planificación del tratamiento para pacientes con cáncer colorrectal metastásico.
Objetive: Determining the RAS gene as a prognostic and predictive factor in metastatic colorectal cancer. Method: This is a descriptive and retrospective study where 67 records of patients with metastatic colorectal cancer were examined, focusing on determining the RAS gene as a prognostic and predictive factor. Results: It was found that 56.7% of patients had Wild-type tumors, while 43.3% showed tumors with KRAS mutations, with no mutations detected in the NRAS gene. Both in the right and left colon, Wild-type tumors were slightly more common than tumors with KRAS mutations. Codon 12 was the most affected in 75.9% of cases of KRAS mutated tumors. Adenocarcinoma was the predominant histological type (82%), followed by mucinous adenocarcinoma (16.5%). Most patients (56.7%) were at stage IV at diagnosis. KRAS mutated tumors showed a higher tendency for recurrence and multiple metastases compared to Wild-type tumors, with the liver and lungs being the most common sites of metastasis. Differences in progression-free survival and overall survival were also observed based on the mutational status of the RAS gene, with higher progression rates in patients with KRAS mutated tumors. Conclusion: These findings suggest that mutations in the KRAS gene could be associated with a poorer prognosis in terms of disease progression and survival. Determining the status of the KRAS gene could have significant clinical implications in risk stratification and treatment planning for patients with metastatic colorectal cancer.
Objetive: Determining the RAS gene as a prognostic and predictive factor in metastatic colorectal cancer. Method: This is a descriptive and retrospective study where 67 records of patients with metastatic colorectal cancer were examined, focusing on determining the RAS gene as a prognostic and predictive factor. Results: It was found that 56.7% of patients had Wild-type tumors, while 43.3% showed tumors with KRAS mutations, with no mutations detected in the NRAS gene. Both in the right and left colon, Wild-type tumors were slightly more common than tumors with KRAS mutations. Codon 12 was the most affected in 75.9% of cases of KRAS mutated tumors. Adenocarcinoma was the predominant histological type (82%), followed by mucinous adenocarcinoma (16.5%). Most patients (56.7%) were at stage IV at diagnosis. KRAS mutated tumors showed a higher tendency for recurrence and multiple metastases compared to Wild-type tumors, with the liver and lungs being the most common sites of metastasis. Differences in progression-free survival and overall survival were also observed based on the mutational status of the RAS gene, with higher progression rates in patients with KRAS mutated tumors. Conclusion: These findings suggest that mutations in the KRAS gene could be associated with a poorer prognosis in terms of disease progression and survival. Determining the status of the KRAS gene could have significant clinical implications in risk stratification and treatment planning for patients with metastatic colorectal cancer.
Description
Type
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/publishedVersion
Source
Science and Health; Vol. 8 No. 2 (2024): Science and Health, april-june; 65-74
Ciencia y Salud; Vol. 8 Núm. 2 (2024): Ciencia y Salud, abril-junio; 65-74
2613-8824
2613-8816
10.22206/cysa.2024.v8i2
Ciencia y Salud; Vol. 8 Núm. 2 (2024): Ciencia y Salud, abril-junio; 65-74
2613-8824
2613-8816
10.22206/cysa.2024.v8i2